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Abstract 
Targeting cancer stem cells (CSCs) can serve as an effective approach toward limiting 
resistance to therapies and the development of metastases in many forms of cancer. While 
basal breast cancers encompass cells with CSC features, rational therapies remain poorly 
established. Here, we show that receptor tyrosine kinase Met signalling promotes the activity 
of the Hippo component YAP in basal breast cancer. Further analysis revealed enhanced 
YAP activity within the CSC population. Using both genetic and pharmaceutical approaches, 
we show that interfering with YAP activity delays basal cancer formation, prevents luminal to 
basal trans-differentiation and reduces CSC survival. Gene expression analysis of YAP 
knock-out mammary glands revealed a strong decrease in β-catenin target genes in basal 
breast cancer, suggesting that YAP is required for nuclear β-catenin activity. Mechanistically, 
we find that nuclear YAP interacts and overlaps with β-catenin and TEAD4 at common gene 
regulatory elements. Analysis of proteomic data from primary breast cancer patients 
identified a significant upregulation of the YAP activity signature in basal compared to other 
breast cancers, suggesting that YAP activity is limited to basal types. Our findings 
demonstrate that in basal breast cancers, β-catenin activity is dependent on YAP signalling 
and controls the CSC program. These findings suggest that targeting the YAP/TEAD4/β-
catenin complex offers a potential therapeutic strategy for eradicating CSCs in basal (triple-
negative) breast cancers. 
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Introduction 
Breast cancer is a heterogeneous human disease that has been classified into various sub-
groups commonly used to plan therapies1–3. The majority of basal breast cancers (~70%) are 
triple-negative for the estrogen receptor (ER), the progesterone receptor (PR) and the 
epidermal growth factor receptor 2 (HER2)2,4. Basal breast cancers are known to display 
high frequencies of gene alterations such as TP53, RB and PTEN, overexpression of WNT 
components, and activating mutations of receptor tyrosine kinases such as the EGFR, MET 
and others5–10. 
Previously we generated a compound mutant mouse model that mimics the key features of 
human basal breast cancers11. It combines the activation of β-catenin, a principal 
downstream component of Wnt signalling12,13, with the expression of HGF, which activates 
the receptor tyrosine kinase Met7,14 under control of the whey acidic protein (WAP) promoter 
(Wnt-Met mice). WAP is naturally expressed in late pregnancy, thus pregnancy stimulates 
the rapid growth of aggressive basal mammary gland tumours in as little as two weeks post-
partum11. Single mutants also develop tumours, but usually over a period of months. Wnt-
Met tumours exhibit basal characteristics, i.e. high levels of basal markers K5, K14 and 
smooth muscle actin, whereas luminal cell markers K8 and K18 were low11. Gene 
expression analysis showed Wnt-Met mutant tumours grouped closely with BRCA1+/-; 
p53+/- basal (triple-negative) but not with luminal breast cancers11,15. Moreover, the 
expression of Wnt target genes Lrp6, Lrp5 and Axin 2 were increased and several 
metastasis-associated genes such as Twist1, CxCr4 and Postn were upregulated. Gene and 
protein expression studies have shown that Met is an essential protein in basal breast 
cancer progression and metastasis10. In addition, Met controls the differentiation state of 
Wnt-Met tumour cells, while Wnt/β-catenin controls the stem cell property of self-renewal11.  
Basal breast cancers exhibit a heterogeneous cellular composition that includes tumour cells 
with stem cell-like properties6,11,16–18. Cancer stem cells (CSCs) have the unique capacity to 
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initiate, maintain and replenish tumours, in contrast to other tumour epithelial cells (TECs), 
which makes them promising targets for cancer therapy19,20. However, a lack of targeted 
treatments generally leads to a poor five-year survival rate for patients presenting to the 
clinic with basal breast cancer21. Current therapeutic options are primarily limited to 
chemotherapeutic agents such as doxorubicin, which are non-specific, toxic and can reduce 
a patient's overall quality of life. Although these drugs are highly effective against 
proliferating cells, they have little effect on CSCs due to their intrinsically low proliferation 
rate2. Increasing the survival rate for basal breast cancer patients will likely require rational 
therapies that target CSCs.  
Here we use Wnt-Met mice to dissect the biochemical pathways of the tumours in search of 
components that could be targeted in therapies directed at CSCs. Our analysis of proteomic 
data available from Mertins et al. of primary tissue from patients revealed a high expression 
of the YAP signature (Yes-associated protein) in basal breast cancer, compared to HER2+, 
Luminal A and Luminal B tumours22. YAP is a critical component of the HIPPO pathway that 
has previously been implicated in the maintenance, survival and expansion of stem cells23–25. 
In this context, its activation is dependent on the upstream kinases LATS1/2 and MST1/2. 
Without these signals, the HIPPO pathway is inactive; this leads to YAP's translocation into 
the nucleus, where it binds the transcriptional activator TEAD 1-4 and triggers gene 
transcription26–28. Recently a number of alternative mechanisms leading to the activation of 
YAP have been described, including the activation of glucocorticoid, the EGF receptor, Wnt 
signalling and intrinsic apoptotic components29–32. The aberrant activation of YAP has been 
shown to have a potent effect on oncogene signalling in breast cancer and many other 
tumours33–36. But this is contradicted by recent studies suggesting that YAP may also 
function as a tumour suppressor, or be irrelevant in breast cancer37,38. We speculated that 
these conflicting data might be due to the context-dependent role of YAP depending on 
tumour heterogeneity or tumour subtype. 
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In this study we set out to elucidate the role of YAP and its regulation in the CSCs underlying 
basal (triple-negative) breast cancers. Proteomic analysis identified that YAP is strongly 
activated by the receptor tyrosine kinase Met, contradicting a recent report suggesting that 
YAP is negatively regulated by RTK signalling39. Our genetic analysis in mice revealed that 
the ablation of YAP delayed tumour formation; cells with ablated YAP were located in 
healthy, single-layered acini with reduced proliferation. Further analyses of Wnt-Met tumours 
found high YAP activity in CD24hiCD49fhi tumour-propagating cells, the generation of which 
was diminished upon YAP ablation. Of clinical relevance, our analysis of publicly available 
data confirmed a higher expression of YAP in the tumours of human patients with basal 
breast cancer than those with luminal breast cancer. In triple-negative human breast 
cancers, high YAP expression strongly correlated with reduced patient survival. Together, 
our findings show that YAP plays a crucial role in the initiation and maintenance of basal 
breast cancer and suggest that targeting YAP may represent a potential strategy for treating 
basal breast cancer. 
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Results 
The receptor tyrosine kinase Met regulates YAP and β-catenin activity at early stages 
of tumorigenesis  
Mice with single Wnt or Met mutations developed discernible mammary gland tumours in 30 
- 40 weeks post-partum (PP), while double mutants exhibited tumours as early as two weeks 
PP (called Wnt-Met tumours)11. This led us to investigate how Wnt and Met co-operate in 
mammary gland tumour formation, and whether their activity is linked to that of YAP22. A 
proteomic analysis of Wnt and Wnt-Met mammary glands at early stages of tumorigenesis 
revealed a strong upregulation of the YAP signature40, indicating that YAP is activated in 
double but not in single mutants (Fig. 1a). We found that at early stages, Wnt-Met double 
mutant mammary glands contained 6-fold more YAP-positive nuclei than mice with only the 
Wnt mutation (Fig. 1b, c). This result was confirmed by Western blotting for active YAP (Fig. 
1d, Supplementary Fig. 1a). Analysis of the phospho-proteome revealed higher levels of 
YAP phosphorylation at S46 and T48, suggesting that these sites play a crucial role in the 
phosphorylation and nuclear activation of YAP (Supplementary Fig. 1b).  
We also examined whether Met signalling is responsible for the nuclear translocation of β-
catenin. Double mutants exhibited a 10-fold increase of nuclear β-catenin compared to the 
mammary glands of mice with only the Wnt mutation (Supplementary Fig. 1c and d). The 
expression of YAP and Wnt target genes including Birc5, Ctgf, Cd44 and Lgr5 was 
significantly higher in the mammary glands of Wnt-Met mice (Fig. 1e)41,42. We also examined 
the expression of YAP and Wnt target genes in Wnt-Met mammospheres43,44 treated with the 
Met inhibitor PHA66575211,40,45. Remarkably, this revealed significantly lower levels in the 
expression of Ctgf, Ccnd1 (CyclinD1) and other genes, confirmed by qPCR (Fig. 1f, 
Supplementary Fig. 1e)40,45. These data show that the RTK Met is required for YAP and β-
catenin nuclear translocation in the mammary glands of Wnt-Met mice. 
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Genetic and pharmacological evidence that basal mammary gland tumours are 
dependent on YAP activity 
Our finding that YAP is highly activated in basal breast cancer led us to examine its 
functional role through genetic and pharmacological interference. We crossed floxed YAP 
alleles46 into Wnt-Met mice. Upon stimulation via pregnancy, this led to homozygous YAP 
ablation in Wnt-Met mice (denoted Wnt-Met-YAPKO) and produced an increase in the 
number of tumour-free mice from 11 days in controls (Wnt-Met and heterozygous YAP 
ablation) to 17days (Fig. 2a). The average weight of Wnt-Met-YAPKO mammary gland 
tumours was also decreased (Fig. 2b). We confirmed YAP ablation by qPCR (Fig. 2c). 
Remarkably, H&E staining and immunohistochemistry of Wnt-Met-YAPKO mammary glands 
revealed large alveoli which were mostly YAP-free and exhibited healthy one-layered acini. 
Their proliferation was lower, as determined by Ki-67 staining (Fig. 2d, lower panel, 
quantification in Fig. 2e). In contrast, Wnt-Met-YAPCtrl mammary glands showed large 
tumorous areas which were strongly YAP-stained, without large, empty alveoli (Fig. 2d, 
upper panel). Fluorescent images of YFP confirmed the successful Cre-recombination of the 
mammary epithelial cells; YFP-positive cells were found in single layered acini in Wnt-Met-
YAPKO glands, in contrast to filled tumours in the controls (Fig. 2f).  
We treated Wnt-Met mice systemically with two inhibitors of YAP activity. Simvastatin (SIM) 
inhibits YAP via the mevalonate-Rho kinase pathway47, and verteporfin (VP) inhibits the 
interaction of YAP with its transcriptional activator TEAD48. Both inhibitors reduced tumour 
volumes and weight (Supplementary Fig. 2a-d). H&E and immunohistochemistry of SIM and 
VP-treated tumours also revealed small, empty alveoli and a strong reduction in Ki-67-
positive cells compared to controls (Supplementary Fig. 2e-j). In combination, these data 
demonstrate that YAP is crucial for tumour initiation in Wnt-Met tumours. 
Met signalling induces the trans-differentiation of luminal mammary gland cells into basal 
cells11,49. To examine whether Met-induced trans-differentiation also depends on YAP, we 
examined Wnt-Met-YAPCtrl and Wnt-Met-YAPKO mammary glands for the expression of the 
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luminal cell maker CK8 and the basal cell marker P63. We observed strong expression of 
P63 in control glands, which exhibited a minimal expression of CK8 (Fig. 2g, h, left panels). 
Strikingly in contrast, Wnt-Met-YAPKO mammary glands showed negligible P63-positive cells 
but a high number of CK8-positive cells (Fig. 2g, h, right panel). As further confirmation, in 
Wnt-Met tumours we found a strong expression of CK14 and a low expression of CK8, a 
pattern which was reversed in SIM-treated tumours (Supplementary Fig. 2k). Overall, these 
data provide genetic and pharmacological evidence that YAP is required for the acquisition 
of basal characteristics in Wnt-Met tumours. 
 
YAP is active in the cancer stem cells of basal mouse mammary gland tumours 
We have previously shown that Wnt-Met tumours induced by WAP-Cre harbour CD24hi and 
CD49fhi/CD29hi cancer stem cells that produce aggressive basal cancers when transplanted 
into immune-deficient mice11. We now examined the contributions of YAP to Wnt-Met CSCs.  
Using an antibody specific for the active state of YAP, we found high levels of nuclear YAP 
on the outer rim of Wnt-Met tumour acini, which correlated to the increase of expression of 
specific stem cell genes such as CD44 and Sox10 (Fig. 3a, Supplementary Fig. 3a, b)18,16,50–
52
. We confirmed high levels of YAP by Western blotting and mRNA expression (Fig. 3b, c). 
Moreover, the expression of target genes of Wnt/β-catenin and YAP including Axin253, 
Ccnd1, Ctgf40 and Igfbp3 increased (Fig. 3d, e).  
High levels of YAP activity have been reported in the stem cell compartments of many 
tissues54,55. CD24hiCD49fhi cancer stem cells were found in the basal cell population of 
mammary gland tumours but not the luminal, as shown by FACS (Fig. 3f, Supplementary 
Fig. 3c). In agreement with this, CSCs have been reported among the basal cells marked by 
cytokeratin 14 (CK14)11,56. We found that YAP was expressed in the nucleus of basal, CK14-
positive cells but not in those that were luminal and CK8-positive (Fig. 3g). Moreover, YAP 
target genes were more highly expressed in CSCs than other tumour epithelial cells (TECs) 
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(Fig. 3h, i). These data show that Wnt-Met signalling generates basal tumours with high YAP 
activity in CSCs of the mammary gland. 
 
YAP regulates growth and initiation of Wnt-Met cancer stem cells 
To study the function of YAP in CSCs, we first established stem cell-enriched control and 
Wnt-Met spheres in mammary gland stem cell-promoting medium57,58 (Supplementary Fig. 
4a). Control spheres (WAP-Cre; ROSA26EYFP) formed structures with single-layered epithelia 
with empty lumens, in contrast to the large, filled structures produced by Wnt-Met spheres 
(Fig 4a, Supplementary Fig. 4b). FACS for YFP showed that Wnt-Met spheres contained 
1.4-fold (57% to 76%) more YFP-positive cells than controls (Supplementary Fig. 4c). They 
also exhibited a higher expression of transgenes, as confirmed by qPCR for Wap, Hgf and 
Lgr5 (Supplementary Fig. 4d). Immunofluorescence demonstrated a decrease in the luminal 
marker CK8 and an increase in the basal marker CK14 (Supplementary Fig. 4e). Moreover, 
a strong nuclear β-catenin signal was observed in the basal cells located at the outer rim of 
these spheres (Fig. 4b). We next isolated cells by FACS and seeded equal cell numbers to 
generate stem cell-enriched spheres. The CSC population underwent an 8-fold higher 
outgrowth than TECs (Supplementary Fig. 4f). These results show that sphere conditions 
enrich and expand CSCs in the Wnt-Met mammary gland tumours. We then identified 
nuclear YAP in tumour-derived spheres through immunofluorescence (Supplementary Fig. 
4g) and quantified the expression of YAP target genes using qPCR. We found a 2.5-fold 
increase in Cyr6140 and 3.7-fold increase in Igfbp340(Supplementary Fig. 4h). 
To understand the functional role of YAP, we inhibited its activity using SIM and VP. These 
treatments reduced proliferation of Wnt-Met spheres, as determined by BrdU and Ki-67 
immunofluorescence (Fig. 4c, quantification on the right, Supplementary Fig. 4i). The 
inhibition of YAP in Wnt-Met spheres reduced the CSCs marked by CD49f 1.25-fold (36% to 
29%) as measured by FACS (Fig. 4d). An expression analysis for the stem cell-associated 
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genes Itga6, Kit59 and Prom160 further supported the inhibition of CSCs (Fig. 4e). Moreover, 
sphere initiation identified by the number of spheres was repressed 2.8-fold by VP (Fig. 4f, 
quantification on the right). Since VP may have off-target affects61 we also treated cells with 
YAP-directed shRNA and siRNA which resulted in a 4-fold decrease of the size of spheres 
generated by Wnt-Met cells and a 2.5-fold decrease in the number of spheres by MDA-231 
cells (Supplementary Fig. 4j-m). FACS analysis revealed a 5.5-fold decrease in the content 
of CD49fhiCD24hi CSCs11 in Wnt-Met-YAPKO mammary glands compared to controls (Fig. 
4g). Furthermore, spheres generated from Wnt-Met-YAPKO mammary glands generated 6-
fold fewer spheres than controls (Fig. 4h, Supplementary Fig. 4n). This demonstrates that 
YAP activity is essential for the growth, initiation and self-renewal of Wnt-Met CSCs. 
 
YAP is required for β-catenin activity in Wnt-Met mammary gland tumours 
We carried out Nanostring gene expression analysis62 of control and Wnt-Met-YAPKO 
mammary glands. Wnt-Met-YAPKO mammary glands exhibited a strong decrease in YAP 
and β-catenin activity (Fig. 5a). This tissue exhibited a downregulation of target genes such 
as Ctgf and Igfpb3 (YAP targets) and Axin2 and BMP4 (β-catenin targets); the same was 
found for VP-treated spheres (Fig. 5b, c, Supplementary Fig. 5a). Quantification showed that 
β-catenin-positive nuclei were decreased 11-fold by the ablation of YAP (Fig. 5d, 
quantification on the right) and a strong decrease by pharmacological inhibition of YAP 
(Supplementary Fig. 5b). 
In the absence of Wnt signalling, an interaction of YAP and β-catenin has been implicated in 
the β-catenin destruction complex30. Here, immunofluorescence revealed that YAP and β-
catenin are co-localized in the nucleus of Wnt-Met spheres and tumours (Fig. 5e). Active 
YAP co-immuno-precipitated with β-cateninGOF and Tead4 in Wnt-Met spheres, but to a 
lesser extent with wildtype β-catenin (Fig. 5f).  
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YAP has been reported to be required for the development of β-catenin driven tumours63. 
Since YAP inhibition resulted in a decrease in the expression of a number of Wnt target 
genes, we hypothesized that YAP/TEAD might bind with β-catenin at promoter and/or 
enhancer regions of common target genes to regulate their expression in CSCs. To test this, 
we obtained YAP1, TEAD4 and CTNNB1 (β-catenin) chIP-seq data from chIP-Atlas64. Since 
YAP has been reported to preferentially bind enhancer regions rather than promoters65, we 
investigated whether YAP/TEAD4/CTNNB1 could occupy an enhancer region of the Wnt 
target gene AXIN253. We identified a distal enhancer of AXIN2 and a strong enhancer of 
NUAK2 (a newly identified YAP target gene66) containing overlapping CTNNB1, TEAD4 and 
YAP1 chIP-seq peaks (Fig. 5g). Overall, these data show that TEAD4, CTNNB1 and YAP1 
interact and can co-locate at gene promoters and enhancers of both Wnt and YAP target 
genes.  
 
YAP is active in human basal breast cancers and predicts patient survival 
The analysis of human primary patient proteomic data available from Mertins et al.22 
revealed high expression of the YAP signature40 in basal breast cancer, in contrast to other 
subgroups of breast cancers (Fig. 6a). qPCR of YAP target genes CTGF, IGFBP3 and 
ANKRD140 in spheres of human basal breast cancer cell lines BT549, MDA231 and 
SUM1315 confirmed elevated YAP activity compared to the luminal cell lines MCF7, BT474 
and T47D (Fig. 6b, Supplementary Fig. 6a). Online datasets available from Gene 
expression-based Outcome for Breast cancer Online (GoBo)67 confirmed a significantly 
higher expression of YAP in tumours of human patients with basal breast cancer than in  
tumours of patients with luminal breast cancer (Supplementary Fig. 6b). 
Immunofluorescence analysis of active YAP in six basal breast cancer PDX models68 
exhibited cells with strong nuclear YAP (Fig. 6c).  
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We also found an opposing correlation between high YAP expression and patient survival in 
luminal (ER+, PR+) breast cancer and basal (triple-negative) (HER2-, ER-, PR-) breast 
cancer, as shown by Kaplan Meier analyses (Fig. 6d, e)69. The high expression of YAP in 
luminal breast cancer correlates with an increase in patient survival, while it correlated with a 
decrease in survival in triple negative breast cancer patients. The high expression of YAP 
target genes such as CTGF, CYR61 and IGFBP3 correlated with reduced survival of 
patients with triple-negative breast cancer (Fig. 6f). Overall, these data show that YAP is 
highly expressed in basal (triple-negative) breast cancers, and its quantification can be used 
to predict patient survival in a subtype-dependent manner. 
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Discussion 
Here we examined the essential role of the transcriptional co-activator YAP in basal breast 
cancer. We identified a key mechanism demonstrating the oncogenic co-operation of Met, 
YAP and β-catenin in basal breast cancer (see schemes in Fig. 7). We show that Met 
signalling controls the nuclear translocation and activation of YAP and β-catenin. Upon 
translocation, YAP and β-catenin interact and bind to enhancer regions of Wnt target genes 
leading to gene transcription. In the absence of YAP, Met signalling can no longer induce the 
nuclear translocation of β-catenin, sequestering it in the cytoplasm and preventing the 
transcription of Wnt target genes. Thus, YAP is a key bottleneck required for the oncogenic 
activity of Met and β-catenin in basal breast cancer.  
YAP activity has been shown to be regulated by several upstream mechanisms10,14,71,70. 
Utilizing our genetic mouse model, proteomic and phosphor-proteomic approaches, we 
found that Met signalling promotes YAP activity. We identified two phosphorylation sites that 
may aid YAP activation. Moreover, our analysis revealed that the regulation of basal 
characteristics by Met depends on YAP. This suggests that YAP might also play a major role 
in the de-differentiation process of other models of basal breast cancers72. Our findings 
demonstrate that Met signalling confers its oncogenic and metastatic abilities through 
activating YAP. It would be interesting to investigate if bypassing the Met receptor by 
overexpression of only YAP and β-catenin lead to tumours that are identical to that of Wnt-
Met.  
Wnt-Met activation generates cancer-propagating cells11. Wnt/β-catenin activity is known to 
be enhanced in CSCs and confers breast cancer re-occurrence and progression73,74. Several 
studies have suggested that Wnt/β-catenin is linked to Hippo/YAP activity30,63,75.  In the 
present study, we found both YAP and β-catenin target genes were increased in Wnt-Met 
tumours. Moreover, we identified active YAP in the CSCs of these tumours. Functionally, we 
show that YAP controls CSC properties: through pharmacological and genetic knockouts of 
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YAP, we demonstrated that the absence of YAP strongly delayed Wnt-Met-driven 
tumorigenesis and decreased the expansion of CD24hiCD49fhi CSCs. Furthermore, we 
established that Wnt/β-catenin target gene expression was decreased upon YAP inhibition, 
demonstrating that YAP is required for Wnt/β-catenin-dependent CSC expansion in Wnt-Met 
tumours.   
Wnt and Hippo signalling have been described as tightly intertwined. For example, in the 
mouse liver, the co-activation of β-catenin and YAP have been shown to lead to the rapid 
generation of hepatocellular carcinoma76. It has been shown that the absence of Wnt signals 
results in YAP/TAZ sequestration in the cytoplasm by the β-catenin destruction complex, 
comprised of APC, Axin and GSK330. In this context, the knockout of YAP/TAZ in embryonic 
stem cells leads to the activation of β-catenin and compensates for loss of Wnt signalling. 
However, we found that genetic ablation of YAP controls β-catenin activity at two levels: i) in 
the nucleus through co-binding the regulatory regions of β-catenin target genes such as 
Axin2, and ii) by regulating β-catenin nuclear translocation, showing that basal breast 
cancers require YAP for nuclear β-catenin activity. It is likely that the master regulatory 
control of Wnt target gene expression by YAP is both context- and tissue-dependent.  
YAP's relevance in breast cancer is currently under dispute. YAP was recently shown to be 
inactive and even downregulated in ductal carcinoma in situ (DCIS)38. In addition, breast 
cancer patients displaying high YAP activity appeared to have a higher overall positive 
prognosis, leading to the belief that YAP might act as a tumour suppressor in breast 
cancer37,77. In this scenario, keeping YAP activity under tight control is thought to help 
tumour cells escape immunosurveillance78. However, other oncogenic transcriptional 
systems are equally likely to stimulate a strong immune response in the host79,80. These 
studies did not investigate the functional role of YAP in a context-dependent manner such as 
breast cancer or tumour cell subtypes. Our study addresses these issues by using genetic, 
siRNA and pharmacological interference with YAP in basal breast cancer to demonstrate its 
function specifically in CSCs. In basal breast cancer, we show that YAP’s genetic ablation 
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strongly delayed Wnt-Met-driven tumorigenesis. Segregation of luminal (ER+, PR+) breast 
cancer patients and basal, triple-negative patients revealed that YAP expression correlated 
with patient survival in opposing ways. High YAP activity was associated with prolonged 
survival in luminal breast cancer patients, but decreased survival in basal/triple-negative 
patients. Thus, YAP appears to function as an oncogene in some cancer subtypes and a 
tumour suppressor gene in others. Further studies will be required to understand what 
mechanisms are responsible for the context-dependent function of YAP and whether its 
inhibition in breast cancer has converse therapeutic benefits in basal and luminal breast 
cancers. 
In conclusion, our data demonstrate that YAP is essential for the co-operation of Wnt and 
RTK (Met) signalling in initiating and maintaining basal mammary gland tumours. We 
demonstrate that Met signalling controls the de-differentiation of luminal to basal mammary 
gland cells through the downstream activation of YAP. Furthermore, we show that YAP is 
highly expressed in the CSCs of Wnt-Met mice and promotes their expansion, partly by 
regulating the activity of β-catenin. We confirmed elevated YAP activity in mammospheres of 
human basal breast cancer cell lines, in tumours from human patients with basal breast 
cancer, and in PDX models of basal breast cancer and contrasted these findings to the 
luminal stages. Our data highlight the importance of YAP as a crucial tumour initiator and 
CSC regulator in basal breast cancer and demonstrate that its activity has prognostic value 
when comparing basal with luminal breast cancers. This suggests that targeting YAP 
through specific new drugs is a potential therapeutic avenue for treating basal breast 
cancers in the future.  
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Methods 
Mice 
All animal experiments were conducted in accordance with European, National and MDC 
regulations. Wnt-Met mutant mice were previously described18 , 24. Yap1tm1.1Dupa/J flox 
mice were purchased from Jackson Laboratories (Stock No: 027929).  Animal experiments 
were approved by the Ethical Board of the ‘Landesamt für Gesundheit und Soziales 
(LaGeSo)’, Berlin. Mice were induced via pregnancy between 8 - 12 weeks old. Tumours 
were harvested between 1 and 2 weeks post-partum and when they reached a maximum 
size of 1cm3. 
 
Isolation of Mammary Gland Cells 
Tumours were minced and digested in DMEM/F12 HAM (Invitrogen) supplemented with 5% 
FBS (Invitrogen), 5µg/ml insulin (Sigma-Aldrich), 0.5µg/ml hydrocortisone (Sigma- Aldrich), 
10ng/ml EGF (Sigma-Aldrich) (D iges tion medium)  containing 300 U/ml Collagenase 
type III (Worthington), 100U/ml Hyaluronidase (Worthington) and 20μg/ml Liberase TM 
(Sigma) at 37°C for 1.5 hours shaking. Resulting organoids were re-suspended in 
0.25% trypsin-EDTA (Invitrogen) at 37°C for 1 minute and fu r t he r dissociated in 
d igest ion medium containing 2 mg/ml Dispase (Invitrogen) and 0.1 mg/ml DNase I 
(Worthington) at 37°C for 45mins while shaking. Samples were filtered with 40 µm cell 
strainers (BD Biosciences) and incubated with 0.8% NH4Cl solution on ice for 3 minutes 
(RBC lysis). Lysis was stopped by washing in 30ml DPBS w/o Ca2+, Mg2+ (Gibco, Cat. 
#14190169). Resulting pellets were used for downstream applications outlined below.  
 
Organotypic Stem Cell-enriched 3D Cultures 
Organotypic stem cell-enriched cultures were generated using previously published 
protocols57,58 with minor adjustments. Single cells from digested mammary glands were re-
suspended and plated on Collagen I-coated plates (50μg/ml) in stem cell-enriching medium 
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MEBM (Lonza Cat. #CC-3151), supplemented with 2% B27 (Invitrogen, Cat. # 17504044), 
20 ng/ml bFGF (Invitrogen, Cat. # 13256029), 20 ng/ml EGF (Sigma, Cat. #SRP3196-
500μg), 4 μg/ml heparin (Sigma, Cat. # H3149), 5 µg/ml insulin (Sigma, Cat. #I0516-5ml), 
0.5µg/ml hydrocortisone (Sigma, Cat. #H0888-1G) and 1X Gentamicin (Sigma, Cat. # 
G1397-100ML) for 16-18 hours. Cells were washed twice with DPBS, washed with 0.25% 
trypsin-EDTA for 30 seconds and then incubated with 0.25% trypsin-EDTA at 37°C for 5 - 7 
minutes until cells detached. Trypsin was inactivated with DMEM/F12 supplemented with 
10% FBS, 1% HEPES and 1% Pen/Strep. Cells were re-suspended in stem-enriching 
medium and counted. Cells were then seeded in 25μl droplets containing 50% reduced 
growth factor Matrigel at a density of 100cells/μl. Plates were carefully flipped and Matrigel 
was let solidify at 37°C for 45mins - 1hour. 0.5ml of stem medium was added per well of 24-
well plates containing a 25μl droplet. Medium was changed every second day.  For 
secondary sphere formation, spheres were dissociated for 10mins in 0.25% trypsin-EDTA, 
and cells were filtered using 0.45μm filters. Single cell suspensions were then re-seeded as 
described for primary cells. 
 
Fluorescence-Activated Cell Sorting (FACS) 
Single cell suspensions from dissociated tumours were re-suspended at 10,000 cells/μl and 
incubated with conjugated primary antibodies at 4°C for 15mins. Cells were then washed x3 
in DPBS and incubated with 7AAD (5μl/106 cells) at room temperature for 5 minutes to stain 
dead/dying cells. Cells were sorted using the FACSAria II or III (BD Biosciences) or analysed 
using LSRFortessa (BD Biosciences). Compensation and unstained controls were carried 
out for every FACS experiment as required. Data were analysed using FLowJo Analysis 
Software.  
 
Histology and Immunostaining 
Mammary glands were fixed overnight at 4°C in 4% formaldehyde (Roth). Glands were then 
dehydrated and embedded in paraffin. For staining, tissue sections were de-paraffinised, 
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rehydrated and stained with Hematoxylin and Eosin (H&E), dehydrated and mounted. 
Images were acquired with a bright-field Zeiss microscope. For immune-staining, antigen-
retrieval was conducted on paraffin-embedded sections by boiling in Tris-EDTA buffer 
(10mmol/L Tris, 1mmol/L EDTA, pH 9.0) for 20 minutes. Cryo-sections were incubated for 5 
minutes at room temperature and then fixed with 4% methanol-free paraformaldehyde for 15 
minutes. Adherent cells were fixed with 4% methanol-free paraformaldehyde for 15mins. 
Stem cell-enriched spheres were collected, centrifuged and then fixed in 4% formaldehyde 
before being dehydrated and paraffin-embedded. All samples were blocked with 10% horse 
serum for 1 hour at room temperature prior to being incubated overnight with primary 
antibodies at 4oC (See Supplementary Table for antibody list). For fluorescent staining, 
samples were incubated with secondary antibodies and DAPI for 1 hour at room temperature 
before being mounted with Immu-mount (Thermo Scientific).  
For immunohistochemistry, after antigen-retrieval, slides were washed and incubated with 
3% H2O2 for 15 minutes at room temperature, washed 3 times for 5 minutes in PBS and 
incubated with primary antibodies overnight at 4oC. Horseradish Peroxidase-labelled 
secondary antibodies were diluted and incubated on slides for 1 hour at room temperature. 
Slides were then washed and developed using DAB chromogenic substrate (DAKO), 
dehydrated and mounted.  
 
Mammary Gland Whole-mount Staining 
Mammary glands were dissected, fixed in Carnoy’s fixative for 2 hours, stained in 
carmine alum solution overnight, de-stained in 70% ethanol, washed in 100% ethanol, 
defatted in xylene overnight, and mounted using Permount (Thermo Scientific). 
 
RNA Isolation, cDNA Generation and qPCR 
RNA was extracted using TRIzol (Invitrogen). For 3D cultures, TRIzol was added directly to 
Matrigel. For tissue, snap frozen glands were pulverised on dry ice, and TRIzol was added to 
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30mg tissue powder. For cell lines, TRIzol was added directly to plate. For mammospheres, 
spheres were collected, pelleted and TRIzol was added. After 5 minutes at room 
temperature, 200μl of chloroform was added per 1ml of TRIzol and shook vigorously by 
hand for 15 seconds. Samples were then centrifuged at 12,000G for 15 minutes. The upper 
phase was transferred to a fresh Eppendorf tube, and 500μl of isopropanol was added, 
mixed and incubated at room temperature for 10 minutes. Samples were then centrifuged at 
12,000G for 10 minutes. The RNA pellet was washed twice with 1ml of 70% EtOH. All steps 
were carried out at 4oC unless otherwise stated. 
cDNA was generated using MMLV reverse transcriptase (Promega). Real time PCR was 
performed using Power Up SybR Green master mix (Thermo Scientific #A25741), see 
Supplementary Table for primer list. GAPDH or RPLO were used as housekeeping genes, to 
which values were normalised to. Bio-Rad CX manager was used to calculate Cq and 
analysed data.  
 
Proteomics and Phospho-proteomics 
For proteomics and phospho-proteomics analysis, sample preparation was carried out 
essentially according to Mertins and collegues, 201881. Briefly, samples were lysed in urea 
lysis buffer containing protease and phosphatase inhibitors. From each sample, 500 µg was 
subjected to reduction with DTT and alkylation with iodoacetamide before performing 
digestion with LysC and trypsin. After desalting, peptides were labelled with TMT6 reagents 
(Thermo) and fractionated by basic reversed-phase separation into 24 fractions. 1.5 µg per 
fraction was injected into LC-MS for global proteome analysis, while the remaining majority 
of the samples were pooled into 12 fractions and enriched for phosphopeptides using robot-
assisted iron-based IMAC on an AssayMap Bravo system (Agilent). 
Proteomics samples were measured on an Exploris 480 orbitrap mass spectrometer 
(Thermo) connected to an EASY-nLC system (Thermo). HPLC-separation occurred on an 
in‐house prepared nano‐LC column (0.074 mm × 250 mm, 1.9 μm Reprosil C18, Dr Maisch 
GmbH) using a flow rate of 250 nl/min on a 110 min gradient with an acetonitrile 
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concentration ramp from 4.7% to 55.2% (v/v) in 0.1% (v/v) formic acid. MS acquisition was 
performed at a resolution of 60,000 in the scan range from 375 to 1,500 m/z. Data-
dependent MS2 scans were carried out at a resolution of 45,000 or 30,000 with an isolation 
window of 0.4 m/z and a maximum injection time of 86 ms (120 ms for phosphoproteomics) 
using the TopSpeed setting with a 1 sec cycle time. Dynamic exclusion was set to 20 s and 
the normalised collision energy was specified to 35. 
For analysis, the MaxQuant software package version 1.6.10.4382,83 was used. TMT6 
reporter ion quantitation was turned on using a PIF setting of 0.5. Variable modifications 
included Met-oxidation, acetylated N-termini and deamidation of Asn and Gln for proteomics 
analysis. For phosphoproteomics analysis, deamidation was replaced by phosphorylation on 
Ser, Thr and Tyr. An FDR of 0.01 was applied for peptides, sites and proteins, and the 
Andromeda search was performed using a mouse Uniprot database (July 2018, including 
isoforms). Further analysis was done using R and the Protigy package 
(https://github.com/broadinstitute/protigy). Protein groups were filtered for proteins that have 
been identified by at least one unique peptide and that had valid TMT reporter ion intensities 
across all samples. The phosphoproteome was also filtered for sites containing valid values 
for all samples. For both analyses, two-sample moderated t-tests (limma package84) 
comparing the two groups were calculated using the log2-transformed and median-MAD 
normalised TMT6 corrected reporter ion intensities, followed by a Benjamini-Hochberg (BH) 
p-value correction. Heatmaps of selected significant proteins or phosphosites according to 
BH-adjusted p-value were generated using the pheatmap package85 employing hierarchical 
clustering based on Euclidean distance. For annotation of gene lists derived from a human 
proteome, i.e. Zanconato and collegues (2016), genes were converted into mouse orthologs 
using biomaRt86 and manual curation. 
 
Nanostring 
PanCancer Pathways panel was purchased from Nanostring including additional custom 
gene set for selected YAP and β-catenin target genes. 70ng of RNA was hybridised for 
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16hours at 65°C. Hybridised RNA was loaded onto and analysed using nCounter SPRINT 
Profiler. Data were analysed using nSolver software. Heatmaps were generated using 
nSolver software from normalised data using Pearson Correlation. Genes included were 
manually filtered using available gene lists40,45. 
 
Protein extraction, Western blot and co-IP 
For Western blotting, protein was extracted using RIPA buffer with added cOMPLETE™ Mini 
protease inhibitor cocktail (#11836153001) and phosphatase inhibitor cocktail 2 and 3 
(Sigma). For 2D cell culture, cells were scraped into RIPA buffer (150mM NaCl, 1% Triton-X-
100, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris pH 8.0 and cOMPLETE™ Mini 
protease inhibitor cocktail (#11836153001) and phosphatase inhibitor cocktail 2 and 3 
(Sigma) for lysis. Lysis was carried out on ice for 20mins, samples were then centrifuged at 
full speed and supernatant was transferred to fresh tubes, and protein concentration was 
measured using BioRad Bradford reagent.  
For co-IP, cells were lysed as above in co-IP buffer (150mM NaCl, 50mM Tris pH 7.5, 1% 
IGPAL-CA-630 (Sigma #I8896), 5% glycerol, 0.5% deoxycholate, 0.1% SDS with 
cOMPLETE™ Mini protease inhibitor cocktail (#11836153001) and phosphatase inhibitor 
cocktail 2 and 3 (Sigma)). Equal amounts of protein were incubated with primary antibodies 
overnight at 4°C rotating. Immuno-complexes were then captured on Dynabeads Protein G 
Invitrogen Cat#10003D for 1 hour at 4°C rotating. Samples were washed and boiled in 
sample buffer and resolved on 10% SDS-PAGE or gradient gels (4 – 20%, Bio-Rad) and 
electro-transferred to PDVF membrane. Membranes were blocked with 5% BSA for 1 hour 
and incubated with primary antibodies (see antibody list).  
 
siRNA 
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siRNAs were purchased from Thermo Scientific (see Supplementary Table for list of specific 
siRNAs). 75pmol/well (6-well) of siRNA was transfected using Lipofectamine 2000 following 
manufacturer’s instructions. Cells were harvested 48 hours post transfection.  
 
shRNA 
PLKO.1 shRNA plasmids were a gift from Yaron Fuchs32. Lentiviral packaging plasmids, 
pMD2.G and psPAX2 were co-transfected along with shscramble and shYAP1 into HEK293 
cells. Viruses were collected and concentrated 24 - 48 hours post-transfection. Concentrated 
viruses were used to transduce Wnt-Met primary mammary cells before being seeded as 
stem cell-enriched spheres.  
 
Cell Culture 
Breast cancer cell lines were purchased from ATCC (MCF10A, MCF7, BT474, T47D, MDA-
MB-231 and BT-549) and Asterand Bioscience (SUM1315 and SUM149). MCF10A cells 
were maintained in DMEM/F12 Glutamax, 5% horse serum, 20ng/ml EGF, 0.5mg/ml 
hydrocortisone, 100ng/ml cholera toxin, 10μg/ml insulin and 1% pen/strep. MCF7, BT474 
and T47D were maintained in DMEM, 10% FBS, 5μg/ml insulin and 1% pen/strep.  MDA-
MB-231 and BT-549 were maintained in DMEM, 10% FBS, 1% NEAAs and 1% pen/strep. 
SUM1315 were maintained in DMEM/F12 HAM-Glutamax, 1% Hepes, 5% FBS, 10ng/ml 
EGF, 5μg/ml insulin and 1% pen/strep. SUM149 were grown in DMEM/F12 HAM-Glutamax, 
1% Hepes, 5% FBS, 1μg/ml hydrocortisone, 5μg/ml insulin and 1% pen/strep. For 
mammosphere assays, cells were seeded at 5,000cells/ml on poly-HEMA-coated non-
adherent 10cm plates in DMEMF12, FGF 10ng/ml, EGF 20ng/ml, ITS 1x and B27 1x. 
Spheres were grown for up to 10 days with medium supplemented every second day.  
 
CellTitre-Glo assay 
3D cultures were seeded into 96-well opaque-walled plates. Control and treated spheres 
with 100μl of medium per well were incubated for 30mins at room temperature. 100μl of 
.CC-BY-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted June 6, 2020. . https://doi.org/10.1101/2020.06.05.115881doi: bioRxiv preprint 
24 
 
CellTiter-Glo reagent was added to each well and incubated for 2 minutes shaking to induce 
cell lysis. Plates were then rested for 10 minutes at room temperature to stabilise the 
luminescent signal. Luminescence was recorded on a luminometer.  
 
In vivo Inhibitor Studies 
For simvastatin treatments, Wnt-Met mice received 100mg/kg of simvastatin or vehicle 
control via oral gavage daily. Simvastatin was diluted in 2% DMSO, 30% PEG 300, 5% 
Tween80 and ddH2O. For verteporfin treatments, mice were treated with 2.5mg/kg daily via 
subcutaneous injection. Verteporfin was diluted in DMSO and then brought to 2.5% DMSO 
in PBS. Tumour volumes and body weight were determined several times per week. 
 
PDX models 
PDX models were established from triple-negative breast cancer patients with their informed 
consent as previously described68. The experimental protocol and animal housing were in 
accordance with institutional guidelines as proposed by the French Ethics Committee 
(Agreement N° B75-05-18). 
 
ChIP-Atlas data analysis 
ChIP-seq tracks for CTNNB1 (SRX833403), TEAD4 (SRX190301) and YAP1 (SRX2844314) 
in H1-hESC were downloaded from chip-atlas.org64,87. Functional annotation for genome 
regions was taken from ChromHMM88. Data were loaded into UCSC genome browser89 to 
make the plots.  
 
Kaplan-Meier and GOBO analysis 
Relapse-free survival of breast cancer patients was analysed using Kaplan-Meier Plotter 
online software (http://kmplot.com). Trichotomization was set to Q1 vs Q4. Expression 
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analysis of YAP in breast cancer cell lines and human datasets were generated using GOBO 
online software (http://co.bmc.lu.se/gobo). 
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Figure Legends 
Figure 1.  HGF-Met signalling regulates YAP activity. a. Heatmap of proteomic analysis 
showing the YAP signature (based on Zanconato et al., 2016) in WAPicre; β-catGOF; 
ROSA26EYFP (Wnt) in comparison to WAPicre; Wap-HGF; β-catGOF ; ROSA26EYFP (Wnt-Met) 
at 1-week PP. The YAP signature proteins shown were significant in a two-sample 
moderated t-test (adj. p-value ≤ 0.05; row-scaling was applied). Values are median-MAD-
normalised across all proteins and row-scaled across all samples. b. Immunofluorescence of 
YFP (green) and active YAP (red) in WAPicre; β-catGOF; ROSA26EYFP (Wnt) and WAPicre; 
Wap-HGF; β-catGOF ; ROSA26EYFP (Wnt-Met) at 1-week PP, scale bar, 20μm. c. 
Quantification of YAP-positive nuclei (YAP+ nuclei/number of nuclei per field x100) in Wnt vs. 
Wnt-Met tissues. Data shown are mean ±SEM, n=3 biological replicates, ***p<0.001, by 
Student’s t test. d. Western blot of active YAP in Wnt and Wnt-Met tissues at 1 week PP. e. 
RT-qPCR of YAP and Wnt target genes in Wnt and Wnt-Met tissues at 1 week PP. Data 
shown are mean ±SEM, n=3 biological replicates, *p<0.05, **p<0.01, by Student’s t-test. f. 
Heatmap of YAP and Wnt target genes of PHA665752-treated mammospheres11.  
 
Figure 2.  Genetic ablation of YAP delays Wnt-Met tumour formation. a. Graph showing 
tumour-free mice in Wnt-Met, Wnt-Met-YAPCtrl and Wnt-Met-YAPKO, **p<0.001, by Gehan-
Breslow-Wilcoxon test.  b. Average tumour weight of Wnt-Met-YAPCtrl and Wnt-Met-YAPKO 
mice. Data shown are mean ±SEM, *p<0.05, by Student’s t-test. c. RT-qPCR of Yap mRNA 
expression in Wnt-Met-YAPCtrl and Wnt-Met-YAPKO tumours. Data shown are mean ±SEM, 
n=3 biological replicates, ***p<0.001, by Student’s t test.  d. Comparison of Wnt-Met-YAPCtrl 
(upper pictures) and Wnt-Met-YAPKO (lower pictures) mammary glands at 2.4 weeks PP. 
H&E staining (left panel), immunohistochemistry of YAP (middle panel) and Ki-67 (right 
panel), red arrowheads mark single cell-layered healthy YAP-free epithelia, scale bar, 50μm 
and 20μm. e. Quantification of Ki-67-positive cells. Data shown are mean ±SEM, n=3 
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biological replicates, *p<0.05, by Student’s t test. f. Confocal images of YFP (green) in Wnt-
Met-YAPCtrl and Wnt-Met-YAPKO mammary glands at 2.4weeks PP, scale bar, 20μm. g. 
Confocal images of YFP (green) and CK8 (red) in Wnt-Met-YAPCtrl and Wnt-Met-YAPKO 
mammary glands at 2.4 weeks PP, scale bar, 20μm. h. Confocal images of YFP (green) and 
P63 (red) in Wnt-Met-YAPCtrl and Wnt-Met-YAPKO mammary glands at 2.4 weeks PP, scale 
bar, 20μm. 
 
Figure 3.  YAP is activated in the CSCs of Wnt-Met-driven mammary gland tumours. a. 
Immunohistochemistry of active YAP in Wnt-Met tumours at 2-weeks post-partum (PP), 
scale bar, 20μm. b. Western blot of control and Wnt-Met tumours at 2 weeks PP showing 
active YAP and GAPDH (above), and quantification of active YAP expression in control and 
Wnt-Met tumours 2-weeks PP (below). Data shown as mean ± SEM, n=3 biological 
replicates **p<0.01 by Student’s t test. c. RT-qPCR of Yap expression in control and Wnt-
Met tumours 2 weeks PP. Data shown as mean ± SEM, n=3 biological replicates ***p<0.001 
by Student’s t test. d. RT-qPCR of Wnt target genes in control and Wnt-Met tumours 2 
weeks PP. Data shown as mean ± SEM, n=3 biological replicates **p<0.01, ***p<0.001  by 
Student’s t-test. e. RT-qPCR of YAP target genes in control and Wnt-Met tumours at 2 
weeks PP. Data shown as mean ± SEM, n=3 biological replicates **p<0.01, ***p<0.001, by 
Student’s t-test. f. FACS for YFP, CD24 and CD49f. g. Immunofluorescence of YAP (green), 
CK8 (red) and CK14 (red), scale bar, 5μm. h. FACS showing isolation of cancer stem cells 
(CSCs) and tumour epithelial cells (TECs). i. RT-qPCR of YAP target genes in TECs and 
CSCs. Data shown are mean ±SEM, n=5 biological replicates, *p<0.05, **p<0.01, 
***p<0.001, by Student’s t-test. 
 
Figure 4.  YAP regulates stem cell properties. a. H&E staining of sectioned stem cell-
enriched spheres generated from control and Wnt-Met tumours, scale bar, 20μm. b. 
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Confocal microscopy of Wnt-Met stem cell-enriched spheres for CK8 (orange), CK14 (green) 
and β-catenin (red), scale bar, 50μm. c. Confocal images of BrdU (green) of stem-enriched 
spheres treated with vehicle control (left) or 2μM verteporfin (right), quantification on the 
right. Data shown are mean ±SEM, n=3 biological replicates, *p<0.05, by Student’s t test.  d. 
FACS histogram showing the number of CD49fhi cells in control or VP-treated stem cell-
enriched spheres, 1.25-fold difference. e. Log2 counts of Itga6, Kit, and Prom1 mRNAs from 
control or VP-treated stem cell-enriched spheres. Data shown are mean ±SEM, n=3 
biological replicates, *p<0.05, by Student’s t-test. f. Bright-field and fluorescent images of 
Wnt-Met stem cell-enriched spheres treated from day one with vehicle control (left) or 2μM 
VP (right). Quantification is on the right, scale bar, 50μm. Data shown are mean ±SEM, n=3 
biological replicates, **p<0.01, by Student’s t test.  g. FACS plot showing the percentage of 
YFP+, CD24hi, CD49fhi cells in Wnt-Met-YAPCtrl and Wnt-Met-YAPKO mammary glands. h. 
Bright-field and fluorescent images of Wnt-Met stem cell-enriched spheres generated from 
Wnt-Met-YAPCtrl and Wnt-Met-YAPKO tissue, scale bar, 20μm. Quantification of sphere 
numbers is on the right. Data shown are mean ±SEM, n=3 biological replicates, ***p<0.001, 
by Student’s t test. 
 
Figure 5.  β-catenin activity is YAP dependent in mammary gland tumours. a. Heat-
map showing differential gene expression of YAP and β-catenin target genes in Wnt-Met-
YAPCtrl and Wnt-Met-YAPKO mice. b. Log2 counts of the YAP target genes Ctgf, Cyr61 and 
Igfbp3. c. Log2 counts of the β-catenin target genes Axin2, Bmp4 and Mycn. Data are mean 
±SEM, n=3 biological replicates, *p<0.05, ***p<0.001, by Student’s t test. d. Confocal 
images of β-catenin (red) in Wnt-Met-YAPCtrl and Wnt-Met-YAPKO mice. Quantification of 
nuclear β-catenin on the right. Data are mean ±SEM, n=3 biological replicates, *p<0.05, by 
Student’s t test. e. Confocal images of β-catenin (red) and active YAP (green) in stem cell-
enriched spheres (upper) and Wnt-Met tumours (lower), scale bar, 10μm. f. Western blot 
showing co-immunoprecipitation of active YAP with β-catenin and TEAD4 in Wnt-Met 
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spheres. g. ChIP-seq tracks for YAP, β-catenin, TEAD4 showing overlapping signals at 
enhancer regions.  
 
Figure 6.  YAP is active in human basal breast tumours and predicts patient outcome 
in a subtype-dependent manner. a. Heatmap of proteomics data from Mertins et al.40. The 
provided CPTAC dataset was filtered for samples that passed the QC criteria. A two-sample 
moderated t-test was applied between samples that have been assigned to basal vs. all 
other subtypes combined. Selected significant proteins from Zanconato et al.40 with an 
adjusted p-value from Benjamini-Hochberg correction < 0.05 from the lists are displayed. 
The heatmap uses median-MAD-normalised input data across all proteins and row-scaling 
across all samples. Hierarchical clustering by Euclidian distance was applied to rows, while 
missing values are indicated by grey colour. Significance as indicated: *adj. p-value < 0.05, 
**adj. p-value < 0.01, ***adj. p-value < 0.001, ****adj. p-value < 0.0001. b. RT-qPCR analysis 
of YAP target genes in luminal (yellow) and basal (blue) cell lines. c. Confocal 
immunofluorescence of nuclear YAP in basal PDX models, scale bar, 20μm. d. Kaplan-
Meier plot showing disease-free survival (DFS) of ER-positive and PR-positive patients with 
high (red) and low (black) YAP expression. e. Kaplan-Meier plot showing disease-free 
survival of triple-negative breast cancer patients with high (red) and low (black) YAP 
expression. f. Kaplan-Meier plot showing the DFS of triple-negative breast cancer patients 
with high (red) and low (black) expression of YAP target genes. 
 
Figure 7.  Schematic model for HGF/Met regulation of β-catenin and YAP activity.  
a. (1) Extracellular HGF binds the Met receptor leading to hetero-dimerization and 
intracellular tyrosine phosphorylation. (2) β-catenin and YAP are activated and translocated 
to the nucleus, (3) where they interact and bind the transcriptional co-activator, TEAD 
leading to the transcription of target genes. b. (1) HGF binds the Met receptor leading to 
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hetero-dimerization and tyrosine phosphorylation. (2) In the absence of YAP, β-catenin is 
sequestered in the cytoplasm, (3) and can no longer induce the transcription of genes such 
as Axin2.  
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Supplementary Figure Legends 
Supplementary Figure 1.  Met signalling regulates YAP and β-catenin. a. Western blot 
for active YAP in triplicates of Wnt and Wnt-Met mammary glands at 1 week PP. b. Heatmap 
of proteomics analysis showing YAP and TAZ (Wwtr1) phosphorylation sites that were 
significant in a two-sample moderated t-test (adj. p-value ≤ 0.1) revealing significant increase 
in YAP phosphorylation at S46 and T48 (row-scaling was applied). The heatmap shows 
median-MAD-normalised input data across all proteins and row-scaling across all samples 
as was clustered based on Euclidian distance. c. Immunofluorescence of YFP (green) and 
β-catenin (red) in WAPicre; β-catGOF; ROSA26EYFP (Wnt) and WAPicre; Wap-HGF; β-catGOF ; 
ROSA26EYFP (Wnt-Met) at 1-week PP, scale bar, 20μm. d. Quantification of β-catenin-
positive nuclei (β-catenin+ nuclei/number of nuclei per field x 100) in Wnt vs. Wnt-Met 
tissues. Data shown are mean ±SEM, n=3 biological replicates, **p<0.01, by Student’s t test.  
e. RT-qPCR of YAP target genes in PHA665752-treated mammospheres. Data shown are 
mean ±SEM, n=2 biological replicates. 
 
Supplementary Figure 2.  Pharmacological evidence of YAP dependency in Wnt-Met 
tumours. a. Tumour volume curve of Wnt-Met tumours treated with vehicle control or 
100mg/kg simvastatin (SIM). Data are mean ±SEM, n=3 biological replicates, ****p<0.0001, 
Two-way ANOVA, Sidak’s multiple comparisons test. b. Average tumour weight of control 
and SIM-treated mice. Data shown are mean ±SEM, n=3 biological replicates, *p<0.05, by 
Student’s t test. c. Tumour volume curve of Wnt-Met tumours treated with vehicle control or 
2.5mg/kg verteporfin (VP). Data are mean ±SEM, n=3 biological replicates, **p<0.01, Two-
way ANOVA, Sidak’s multiple comparisons test d. Average tumour weight of control and VP 
treated mice. Data shown are mean ±SEM, n=3 biological replicates, *p<0.05, by Student’s t 
test. e. H&E staining of control and SIM treated Wnt-Met tumours, scale bar, 50μm. f. 
Immunohistochemistry of Ki-67 in control and SIM-treated tumours, scale bar, 20μm. g. 
.CC-BY-ND 4.0 International licensewas not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (whichthis version posted June 6, 2020. . https://doi.org/10.1101/2020.06.05.115881doi: bioRxiv preprint 
41 
 
Quantification of Ki-67-positive cells/area in control and SIM-treated tumours. Data shown 
are mean ±SEM, n=3 biological replicates, **p<0.01, by Student’s t test. h. H&E staining of 
control and VP-treated Wnt-Met tumours, scale bar, 50μm. i. Immunohistochemistry of Ki-67 
in control and SIM-treated tumours, scale bar, 20μm. j. Quantification of Ki-67-positive 
cells/area in control and SIM-treated tumours. Data shown are mean ±SEM, n=3 biological 
replicates, **p<0.01, by Student’s t test. k. Immunofluorescent images of control and SIM-
treated tumours for CK8 (red), CK14 (white) and YFP (green), scale bar, 20μm.  
 
Supplementary Figure 3.  YAP is activated in CSCs of Wnt-Met-driven mammary gland 
tumours. a. Confocal analysis of YAP in control and Wnt-Met tumours, scale bar, 10μm. b. 
qRT-PCR of stem cell genes in Control and Wnt-Met mammary glands. Data shown are 
mean ±SEM, n=3 biological replicates, **p<0.01, ***p<0.001, by Student’s t-test. c. RT-
qPCR of Cd29 and Cd49f in TECs and CSCs. Data shown are mean ±SEM, n=3 biological 
replicates, *p<0.05, by Student’s t-test. 
 
Supplementary Figure 4.  Stem cell-enriched spheres recapitulate in vivo cell 
phenotypes. a. Scheme showing the method used to isolate and generate stem cell-
enriched spheres. b. Bright-field and fluorescent images of stem cell-enriched spheres 
generated from control or Wnt-Met mammary glands at 2 weeks PP, scale bar, 50μm. c. 
FACS histogram showing YFP-positive cells in control or Wnt-Met derived stem-enriched 
spheres. Fold-change calculated by YFP cells in Wnt-Met/YFP cells in control. d. RT-qPCR 
of transgene-associated genes in control or Wnt-Met stem cell-enriched spheres. Data 
shown are mean ±SEM, n=3 biological replicates, *p<0.05, **p<0.01, by Student’s t test. e. 
Confocal images of CK8 (red), CK14 (white) and YFP (green) in control and Wnt-Met stem 
cell-enriched spheres, scale bar, 50μm. f. Fluorescent images showing YFP in stem cell-
enriched spheres generated from FACS-isolated TECs and CSCs. Quantification of sphere 
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numbers (right). Data shown are mean ±SEM, n=3 replicates, **p<0.01, by Student’s t-test. 
g. Confocal images of YAP (green) in Wnt-Met stem cell-enriched spheres, scale bar, 50μm. 
h. RT-qPCR YAP target genes in control and Wnt-Met stem cell-enriched spheres. Data 
shown are mean ±SEM, n=3 biological replicates, *p<0.05, **p<0.01, by Student’s t-test. i. 
Confocal images of Ki-67 (green) in control and 2.5μM simvastatin (SIM)-treated stem cell-
enriched spheres, scale bar, 50μm. j. Fluorescent images of the H2B-RFP reporter in Wnt-
Met stem cell-enriched spheres, scale bar, 50μm. Quantification of sphere numbers on the 
right. Data shown are mean ±SEM, n=3 biological replicates, *p<0.05, by Student’s t test. k. 
RT-qPCR of Yap in sh-treated control (Ctrl) and shYAP Wnt-Met spheres. l. Western Blot for 
YAP in sicontrol and siYAP treated MDA-231 cells, GAPDH was used as a loading control. 
m. Bright-field images of spheres generated from sicontrol and siYAP treated MDA-231 
cells. Quantification of sphere numbers on the right. Data shown are mean ±SEM, n=3 
replicates ***p<0.001 by Student’s t test. n. RT-qPCR of Yap in Wnt-Met-YAPCtrl and Wnt-
Met-YAPKO spheres.  
 
Supplementary Figure 5.  YAP controls β-catenin activity. a. RT-qPCR of YAP and β-
catenin target genes in Wnt-Met mammary gland spheres treated with 2µM verteporfin (VP) 
for 48Hrs. Data shown are mean ±SEM, n=3 biological replicates, *p<0.05, **p<0.01, by 
Student’s t-test.  b. Confocal images of β-catenin (green) in control and SIM-treated stem 
cell-enriched spheres, scale bar, 50μm.  
 
Supplementary Figure 6.  YAP is active in human basal breast tumours and predicts 
patient outcome in a subtype-dependent manner. a. Bright-field images of spheres 
generated from basal (lower) and luminal (upper) cell lines. Scale bar, 100µm. b. Box-plot 
showing YAP1 expression in basal and luminal breast tumours.  
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